Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2021-09-19 AGM Information
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 25 pages 916.0KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM TO SHAREHOLDERS' and includes detailed agenda items for the AGM such as receiving financial reports, resolutions for adoption of remuneration report, re-election of a director, approval of placement capacity, employee securities incentive plan, and renewal of proportional takeover provisions. It also contains instructions on voting procedures, proxy appointments, and other meeting logistics. The document does not contain the actual financial reports or detailed financial data but rather serves as a notice and explanatory memorandum for the upcoming AGM. Therefore, this document is best classified as AGM Information (AGM-R).
2021-09-19 English
Letter to Shareholders - Annual General Meeting 1 p
AGM Information Classification · 95% confidence The document is a notice to shareholders about the upcoming Annual General Meeting (AGM) of Botanix Pharmaceuticals Limited, including details about the meeting date, location, proxy voting instructions, and COVID-19 related arrangements. It explicitly refers to the Notice of Annual General Meeting and proxy form, and it is dated well before the meeting date. The document is short (2496 characters) and does not contain any financial data, results, or presentations. It is essentially an announcement and proxy solicitation related to the AGM. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related notices. It is not a full Annual Report or proxy solicitation statement (PSI), but a notice and proxy form for the AGM itself.
2021-09-19 English
Botanix Presentation Corporate Update 24 pages 5.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Botanix Presentation Corporate Update' dated 1 September 2021 and is described as a corporate presentation used for investor meetings. It contains detailed information about the company's clinical studies, pipeline, financial position, management team, and market overview. The text explicitly states that it is a presentation being utilized in meetings with investors. There are no financial statements or detailed financial analysis typical of annual or interim reports. It is not an earnings release or regulatory filing. The content and format align with an Investor Presentation, which focuses on financials, strategy, and market position for investors.
2021-08-31 English
Annual General Meeting 2 pages 122.5KB
AGM Information Classification · 95% confidence The document is an announcement dated 27 August 2021 regarding the scheduling of the company's 2021 Annual General Meeting (AGM) to be held on 26 October 2021. It includes details about the AGM such as the re-election of directors and the deadline for director nominations. There is no detailed report, financial data, or presentation content included. The document is short (4091 characters) and serves as a notification about the upcoming AGM rather than the AGM materials themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to the AGM event.
2021-08-26 English
Apendix 4G 13 pages 290.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed key to corporate governance disclosures, indicating compliance with governance principles and recommendations for the financial year ended 30 June 2021. The document is not the full annual report but a supplementary governance disclosure document that accompanies the annual report. It includes references to where governance disclosures can be found (e.g., pages 54 to 63 of the annual report or a URL). The document is lengthy (15,000 characters) and contains detailed governance information, but it is not the full annual report itself. It is a regulatory filing required by the ASX to confirm compliance with governance disclosure rules. This type of document fits best under Regulatory Filings (RNS) as it is a compliance document related to governance disclosures and not the full annual report or a governance report itself.
2021-08-26 English
Final Report and Annual Report to Shareholders 70 pages 1.3MB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Final report' and includes detailed financial information for the year ended 30 June 2021, including consolidated statements of profit or loss, financial position, cash flows, notes to financial statements, directors' report, auditor's report, and corporate governance statement. It references compliance with accounting standards and includes a comprehensive directors' report with detailed management discussion and financial results. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content and structure align with an official annual report covering full financial performance and company activity for the fiscal year. Therefore, the document is best classified as an Annual Report (10-K equivalent).
2021-08-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.